Changing paradigm in advanced and metastatic non-small cell lung cancer

Dipesh Uprety, Kaushal Parikh, Anita Sawkar, Anastasios Dimou, Konstantinos Leventakos

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Lung cancer is the most common cancer worldwide. Approximately 18% of all deaths related to cancer are associated with lung cancer. Management of non-small cell lung cancer (NSCLC) has been changing rapidly in last few years. For patients with unresectable non-metastatic disease, maintenance durvalumab is now given after offering chemo-radiation concurrently based on the result from the PACIFIC trial. Management of metastatic disease greatly depends on the status of sensitizing driver mutation and PDL1 level of the tumor cells. In this review article, we will summarize the outcome of various clinical trials and will provide the most up-to-date information on the management of patients with advanced and metastatic NSCLC.

Original languageEnglish (US)
Pages (from-to)6992-7001
Number of pages10
JournalJournal of Thoracic Disease
Issue number11
StatePublished - Nov 2020


  • Advanced
  • Lung cancer
  • Metastatic
  • Non-small cell lung cancer (NSCLC)
  • Stage III
  • Stage IV

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Changing paradigm in advanced and metastatic non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this